文献速递帕金森病与运动障碍

LRRK2突变对帕金森病临床期与临床前期胆碱能系统的影响:一项横断面PET研究

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
PubMed 文献 · Lancet Neurol · 2018-02-16

该横断面PET研究在加拿大、挪威和美国四家运动障碍门诊招募了14例LRRK2帕金森病患者、16例无帕金森病的LRRK2突变携带者、8例特发性帕金森病患者和11例健康对照,用N-11C-甲基哌啶-4-基丙酸酯PET检测乙酰胆碱酯酶活性,发现LRRK2突变携带者胆碱能活性显著升高,作者认为这可能反映对LRRK2相关功能障碍的早期持续代偿尝试或非神经元细胞乙酰胆碱酯酶改变。

要点

  • 无帕金森病的LRRK2突变携带者皮层乙酰胆碱酯酶水解率较健康对照升高(平均皮层p=0·046)。
  • LRRK2帕金森病患者部分皮层区域和丘脑乙酰胆碱酯酶活性显著高于特发性帕金森病患者(平均皮层p=0·043,默认模式网络相关区域p=0·021,丘脑p=0·004)。
  • 健康对照的乙酰胆碱酯酶水解率与年龄呈负相关。

核心结论

  • LRRK2突变与突变携带者(无帕金森病)较健康对照、以及LRRK2突变携带者合并帕金森病较特发性帕金森病患者脑内胆碱能活性显著升高相关。
  • 胆碱能活性改变可能代表对LRRK2相关功能障碍的早期持续代偿尝试,或非神经元细胞乙酰胆碱酯酶的改变。

研究设计与样本

  • 横断面PET研究,2009年6月至2015年12月从加拿大、挪威和美国四家运动障碍门诊招募参与者。
  • 纳入14例LRRK2帕金森病患者、16例无帕金森病的LRRK2突变携带者、8例特发性帕金森病患者和11例健康对照。
  • 帕金森病由运动障碍神经科医生依据英国帕金森病学会脑库标准诊断,LRRK2携带状态经双向Sanger测序确认。
  • 使用PET示踪剂N-11C-甲基哌啶-4-基丙酸酯扫描乙酰胆碱酯酶活性,主要结局为用纹状体输入法计算的乙酰胆碱酯酶水解率。
  • 采用ANCOVA比较组间乙酰胆碱酯酶水解率,并根据线性回归分析结果对年龄进行调整。

主要发现

  • 组间乙酰胆碱酯酶水解率在皮层区域存在显著差异(平均皮层p=0·009,默认模式网络相关区域p=0·006,边缘网络相关区域p=0·020),丘脑差异亦显著(p=0·008)。
  • 无帕金森病的LRRK2突变携带者较健康对照皮层乙酰胆碱酯酶水解率升高(平均皮层p=0·046)。
  • LRRK2帕金森病患者较特发性帕金森病患者部分皮层区域乙酰胆碱酯酶活性显著升高(平均皮层p=0·043,默认模式网络相关区域p=0·021),丘脑亦显著升高(p=0·004)。
  • 健康对照的乙酰胆碱酯酶水解率与年龄呈负相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Markers of neuroinflammation are increased in some patients with LRRK2 Parkinson's disease compared with individuals with idiopathic Parkinson's disease, suggesting possible differences in disease pathogenesis. Previous PET studies have suggested amplified dopamine turnover and preserved serotonergic innervation in LRRK2 mutation carriers. We postulated that patients with LRRK2 mutations might show abnormalities of central cholinergic activity, even before the diagnosis of Parkinson's disease. METHODS: Between June, 2009, and December, 2015, we recruited participants from four movement disorder clinics in Canada, Norway, and the USA. Patients with Parkinson's disease were diagnosed by movement disorder neurologists on the basis of the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. We used the PET tracer N-11C-methyl-piperidin-4-yl propionate to scan for acetylcholinesterase activity. The primary outcome measure was rate of acetylcholinesterase hydrolysis, calculated using the striatal input method. We compared acetylcholinesterase hydrolysis rates between groups using ANCOVA, with adjustment for age based on the results of linear regression analysis. FINDINGS: We recruited 14 patients with LRRK2 Parkinson's disease, 16 LRRK2 mutation carriers without Parkinson's disease, eight patients with idiopathic Parkinson's disease, and 11 healthy controls. We noted significant between-group differences in rates of acetylcholinesterase hydrolysis in cortical regions (average cortex p=0·009, default mode network-related regions p=0·006, limbic network-related regions p=0·020) and the thalamus (p=0·008). LRRK2 mutation carriers without Parkinson's disease had increased acetylcholinesterase hydrolysis rates compared with healthy controls in the cortex (average cortex, p=0·046). Patients with LRRK2 Parkinson's disease had significantly higher acetylcholinesterase activity in some cortical regions (average cortex p=0·043, default mode network-related regions p=0·021) and the thalamus (thalamus p=0·004) compared with individuals with idiopathic disease. Acetylcholinesterase hydrolysis rates in healthy controls were correlated inversely with age. INTERPRETATION: LRRK2 mutations are associated with significantly increased cholinergic activity in the brain in mutation carriers without Parkinson's disease compared with healthy controls and in LRRK2 mutation carriers with Parkinson's disease compared with individuals with idiopathic disease. Changes in cholinergic activity might represent early and sustained attempts to compensate for LRRK2-related dysfunction, or alteration of acetylcholinesterase in non-neuronal cells. FUNDING: Michael J Fox Foundation, National Institutes of Health, and Pacific Alzheimer Research Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Liu SY, Wile DJ, Fu JF, et al. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Lancet Neurol. 2018. PMID: 29456161. doi:10.1016/S1474-4422(18)30032-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。